With regard to MSS/MSI-RNF43 status, 22% of patients were MSS-RNF43mutated and 78% were MSS-RNF43wild-type, similar to the discovery and validation MSS tumor cohorts (29% and 71%, respectively) (Extended Data ﻿Fig. 7a–c and Supplementary Table 1). The gene discussed is RNF43; the disease is neoplasm.